Chemistry:Fipravirimat
From HandWiki
Short description: HIV/AIDS treatment experimental drug
| Error creating thumbnail: Unable to save thumbnail to destination | |
| Clinical data | |
|---|---|
| Other names | GSK3640254 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C43H67FN2O4S |
| Molar mass | 727.08 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fipravirimat is an experimental drug for the treatment of HIV/AIDS. It belongs to a class of drugs known as maturation inhibitors.[1][2]
Fipravirimat was being developed by ViiV Healthcare, but development was stopped in 2023.[3]
See also
References
- ↑ "Fipravirimat". PubChem. U.S. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/Fipravirimat.
- ↑ "GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile". Antimicrobial Agents and Chemotherapy 66 (1): e0187621. January 2022. doi:10.1128/AAC.01876-21. PMID 34780263.
- ↑ Waldron, James (2023-04-26). "GSK drops one of 2 maturation inhibitors in HIV pipeline". https://www.fiercebiotech.com/biotech/gsk-drops-one-two-maturation-inhibitors-hiv-pipeline.
